Medicines Adaptive Pathways to Patients: Why, When, and How to Engage?
Eichler HG., Bedlington N., Boudes M., Bouvy JC., Broekmans AW., Cerreta F., Faulkner SD., Forda SR., Joos A., Le Cam Y., Mayer MH., Pirard V., Corriol-Rohou S.
Medicines Adaptive Pathways to Patients (MAPPs) seeks to foster access to novel beneficial treatments for the right patient groups at the earliest appropriate time in the product life-span, in a sustainable fashion. We summarize the MAPPs engagement process and critical questions to be asked at each milestone of the product life-span. These considerations are of relevance for regulatory and access pathways that strive to address the “evidence vs. access” conundrum.